CD8A and myeloid sarcoma: Identifying the target antigens by tissue-hosting CD8+ T cells and B cells and recognizing the molecular properties and corresponding gene targets of soluble inflammatory mediators that may cause tissue damage are conducive to the treatment of MS [41].